

Erlotinib EURTAC

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE




ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Erlotinib EURTAC

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies
Therapeutic Indication: Locally advanced or metastatic NSCLC with EGFR activating mutations
Experimental Arm: Erlotinib
Control Arm: Platinum-based chemotherapy doublet



